Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Your chemo is no good here: management of high-risk MCL.

Hematology. American Society of Hematology. Education Program - 6 Dec 2024

Sawalha Yazeed, Maddocks Kami

Abstract excerpt

Historically considered a lymphoma with limited treatment options and poor outcomes, the treatment landscape in mantle cell lymphoma (MCL) has evolved remarkably in the last decade. Chemoimmunotherapy (CIT) remains the primary frontline treatment for most patients with MCL, typically with an intensive approach in younger and fit patients. The role of consolidative autologous stem cell transplantation remains...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CIT gene
Share to Hematopoietic Stem Cell Transplantation
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, Mantle-Cell

Share to Mutation

Share to Quality of Life

Share to Transplantation, Autologous

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 39644043
DOI: 10.1182/hematology.2024000658
PMCID: PMC11665716

Genes

CIT
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Your chemo is no good here: management of high-risk MCL.PMID 39644043Read ↗

Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma.Semantic proximity Read ↗

Unraveling MCL biology to understand resistance and identify vulnerabilitiesSemantic proximity Read ↗

Mantle cell lymphoma: evolving management strategies.Semantic proximity Read ↗

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.Semantic proximity Read ↗

Biological and clinical determinants shaping heterogeneity in mantle cell lymphomaSemantic proximity Read ↗

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.Semantic proximity Read ↗

Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions.Semantic proximity Read ↗

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsSemantic proximity Read ↗

Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.Semantic proximity Read ↗

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraSemantic proximity Read ↗

Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphomaSemantic proximity Read ↗

Novel agents for mantle cell lymphoma: molecular rational and clinical data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.